Compare Stocks: ATNM, HUMA, TNYA, and OTLK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.22 +2.5%	$0.99	$0.74 ▼ $1.74	$38.36M	0.05	149,039 shs	146,206 shs
HUMA Humacyte	$0.59 +1.8%	$0.64	$0.53 ▼ $2.55	$162.68M	2.45	4.92 million shs	6.99 million shs
OTLK Oncobiologics	$0.65 -4.2%	$0.92	$0.16 ▼ $2.54	$158.87M	0.74	6.19 million shs	5.60 million shs
TNYA Tenaya Therapeutics	$0.68 +1.1%	$0.73	$0.53 ▼ $2.35	$152.32M	2.77	1.64 million shs	4.85 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	+2.52%	-12.86%	+7.96%	+18.45%	-24.22%
HUMA Humacyte	+1.83%	+3.17%	-20.32%	-36.65%	-61.73%
OTLK Oncobiologics	-4.17%	-1.12%	-5.43%	-58.70%	-36.02%
TNYA Tenaya Therapeutics	+1.06%	+6.14%	-4.71%	-7.02%	-44.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.22 +2.5%	$0.99	$0.74 ▼ $1.74	$38.36M	0.05	149,039 shs	146,206 shs
HUMA Humacyte	$0.59 +1.8%	$0.64	$0.53 ▼ $2.55	$162.68M	2.45	4.92 million shs	6.99 million shs
OTLK Oncobiologics	$0.65 -4.2%	$0.92	$0.16 ▼ $2.54	$158.87M	0.74	6.19 million shs	5.60 million shs
TNYA Tenaya Therapeutics	$0.68 +1.1%	$0.73	$0.53 ▼ $2.35	$152.32M	2.77	1.64 million shs	4.85 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	+2.52%	-12.86%	+7.96%	+18.45%	-24.22%
HUMA Humacyte	+1.83%	+3.17%	-20.32%	-36.65%	-61.73%
OTLK Oncobiologics	-4.17%	-1.12%	-5.43%	-58.70%	-36.02%
TNYA Tenaya Therapeutics	+1.06%	+6.14%	-4.71%	-7.02%	-44.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	309.84% Upside
HUMA Humacyte	2.71	Moderate Buy	$6.54	1,017.09% Upside
OTLK Oncobiologics	2.20	Hold	$5.20	696.81% Upside
TNYA Tenaya Therapeutics	2.86	Moderate Buy	$4.00	488.84% Upside

Current Analyst Ratings Breakdown

Latest ATNM, HUMA, TNYA, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$4.00
8/13/2026	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$2.00 ➝ $1.00
8/12/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
7/28/2026	OTLK Oncobiologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
7/27/2026	OTLK Oncobiologics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$1.60
7/27/2026	OTLK Oncobiologics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00
7/8/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	TNYA Tenaya Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$35.09M	1.09	N/A	N/A	$1.31 per share	0.93
HUMA Humacyte	$2.04M	79.74	N/A	N/A	$0.02 per share	29.28
OTLK Oncobiologics	$1.35M	117.69	N/A	N/A	($0.60) per share	-1.09
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$0.57 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
OTLK Oncobiologics	-$62.42M	-$0.77	N/A	N/A	N/A	N/A	N/A	-254.82%	N/A
TNYA Tenaya Therapeutics	-$90.60M	-$0.53	N/A	N/A	N/A	N/A	-83.75%	-66.53%	11/11/2026 (Estimated)

Latest ATNM, HUMA, TNYA, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	OTLK Oncobiologics	-$0.08	-$0.09	-$0.01	-$0.15	$0.97 million	$0.01 million
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/5/2026	Q2 2026	TNYA Tenaya Therapeutics	-$0.0683	-$0.20	-$0.1317	-$0.20	$10.00 million	$1.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
HUMA Humacyte	2.07	6.21	5.74
OTLK Oncobiologics	N/A	0.81	0.63
TNYA Tenaya Therapeutics	N/A	4.52	4.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
HUMA Humacyte	44.71%
OTLK Oncobiologics	11.20%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.60%
HUMA Humacyte	3.10%
OTLK Oncobiologics	1.80%
TNYA Tenaya Therapeutics	2.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	25	31.44 million	29.32 million	Optionable
HUMA Humacyte	184	277.80 million	269.19 million	Optionable
OTLK Oncobiologics	17	243.45 million	239.07 million	Optionable
TNYA Tenaya Therapeutics	70	224.23 million	218.56 million	Optionable

ATNM, HUMA, TNYA, and OTLK Headlines

Recent News About These Companies

Tenaya Therapeutics Announces RMAT Designation To TN-401

September 14, 2026 | rttnews.com

Tenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock Up

September 14, 2026 | rttnews.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...

September 14, 2026 | finance.yahoo.com

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

September 14, 2026 | globenewswire.com

Tenaya op H.C. Wainwright-conferentie: gentherapiedata

September 11, 2026 | nl.investing.com

Tenaya Therapeutics Corporate Event Calendar | NASDAQ:TNYA

September 11, 2026 | benzinga.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $4.00 Average PT from Analysts

September 10, 2026 | americanbankingnews.com

BlackRock Inc. Acquires New Stake in Tenaya Therapeutics, Inc. $TNYA

September 6, 2026 | marketbeat.com

Wall Street Zen Upgrades Tenaya Therapeutics (NASDAQ:TNYA) to Sell

September 6, 2026 | marketbeat.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 3, 2026 | globenewswire.com

Tenaya Therapeutics (NASDAQ:TNYA) Cut to Strong Sell at Wall Street Zen

August 29, 2026 | marketbeat.com

1,555,500 Shares in Tenaya Therapeutics, Inc. $TNYA Purchased by ADAR1 Capital Management LLC

August 26, 2026 | marketbeat.com

Empery Asset Management LP Takes $2.86 Billion Position in Tenaya Therapeutics, Inc. $TNYA

August 22, 2026 | marketbeat.com

Faraz Ali Sells 22,232 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

August 18, 2026 | insidertrades.com

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

August 14, 2026 | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA) and Viridian Therapeutics (VRDN)

August 7, 2026 | theglobeandmail.com

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026 | globenewswire.com

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 4, 2026 | globenewswire.com

Cours Tenaya Therapeutics, Inc.

July 29, 2026 | zonebourse.comZ

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

July 14, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATNM, HUMA, TNYA, and OTLK Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.22 +0.03 (+2.52%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.23 +0.01 (+0.82%)

As of 09/18/2026 06:17 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Humacyte NASDAQ:HUMA

$0.59 +0.01 (+1.83%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.59 +0.00 (+0.07%)

As of 09/18/2026 07:55 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Oncobiologics NASDAQ:OTLK

$0.65 -0.03 (-4.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.68 +0.03 (+4.20%)

As of 09/18/2026 07:51 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Tenaya Therapeutics NASDAQ:TNYA

$0.68 +0.01 (+1.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.69 +0.01 (+0.99%)

As of 09/18/2026 07:57 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, HUMA, TNYA, and OTLK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, HUMA, TNYA, and OTLK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, HUMA, TNYA, and OTLK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATNM, HUMA, TNYA, and OTLK Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Humacyte NASDAQ:HUMA

Oncobiologics NASDAQ:OTLK

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, HUMA, TNYA, and OTLK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, HUMA, TNYA, and OTLK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, HUMA, TNYA, and OTLK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATNM, HUMA, TNYA, and OTLK Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Humacyte NASDAQ:HUMA

Oncobiologics NASDAQ:OTLK

Tenaya Therapeutics NASDAQ:TNYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools